A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs UCB 7858 (Primary) ; UCB 7858 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors UCB
- 07 Feb 2018 Status changed from active, no longer recruiting to completed.
- 11 Sep 2017 Planned End Date changed from 1 Sep 2017 to 25 Jan 2018.
- 11 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 25 Jan 2018.